GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » YoY EBITDA Growth

Estrella Immunopharma (Estrella Immunopharma) YoY EBITDA Growth : 83.33% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Estrella Immunopharma's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 83.33%.

Estrella Immunopharma's EBITDA per Share for the three months ended in Mar. 2024 was $-0.01.

Estrella Immunopharma YoY EBITDA Growth Historical Data

The historical data trend for Estrella Immunopharma's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma YoY EBITDA Growth Chart

Estrella Immunopharma Annual Data
Trend Jun21
YoY EBITDA Growth
-

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,500.00 -1,460.00 -70.97 64.63 83.33

Estrella Immunopharma YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Estrella Immunopharma's YoY EBITDA Growth for the fiscal year that ended in Jun. 2021 is calculated as:

YoY EBITDA Growth (A: Jun. 2021 )
=(EBITDA per Share (A: Jun. 2021 )-EBITDA per Share (A: . 20 ))/ | EBITDA per Share (A: . 20 ) |
=(-0.021-)/ | |
=N/A %

Estrella Immunopharma's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(-0.013--0.078)/ | -0.078 |
=83.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Estrella Immunopharma YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Estrella Immunopharma (Estrella Immunopharma) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » YoY EBITDA Growth
Comparable Companies
EYEN FGEN ADCT VANI IPA AFMD KNTE KZR SABS ELTX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Website
https://www.estrellabio.com
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma (Estrella Immunopharma) Headlines

No Headlines